Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi September 6, 2024 Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease View All News Events September 6, 2024at 1:05 PM EDT ...
Sanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright Sep. 23, 2024 at 12:15 p.m. ET on TipRanks.com Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences Sep. 23, 2024 at 11:13 a.m. ET on Benzinga.com Ventyx Biosciences announces $27M investment...
Sanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright Sep. 23, 2024 at 12:15 p.m. ETon TipRanks.com Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences Sep. 23, 2024 at 11:13 a.m. ETon Benzinga.com ...
VTYX announced a $27 million strategic investment from Sanofi at $3.82 per share, with Sanofi purchasing 70,601 Series A preferred shares, convertible into 100 common shares each.#biotech# #Seeking# $Ventyx Biosciences(VTYX)$For TYK2 发行公告 Ventyx Biosciences(VTYX)10-01 04:45 $Ventyx Biosc...